Picture loading failed.

Pre-Made Bimekizumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bimekizumab (INN) is a humanized anti-IL17A and IL-17F monoclonal antibody[2] that is being investigated for ankylosing spondylitis, psoriatic arthritis, and psoriasis.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-070-1mg 1mg 3090
GMP-Bios-ab-070-10mg 10mg 21890
GMP-Bios-ab-070-100mg 100mg 148000
GMP-Bios-ab-070-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Bimekizumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody
INN Name Bimekizumab
TargetIL17
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesUCB
Conditions ApprovedPlaque psoriasis
Conditions ActiveAnkylosing spondylitis;Psoriatic arthritis;Hidradenitis suppurativa;Ulcerative colitis;Axial spondylarthritis
Conditions DiscontinuedPsoriasis;Rheumatoid arthritis
Development Techna